Your daily pharma scoop: ACADIA’s growth potential, Lexicon’s Diabetes Troubles, Neos down post-approval
- ACADIA’s growth potential in PDP and also in ADP is discussed.
- Lexicon’s slump following positive data and its interpretation by a Seeking Alpha contributor is analyzed.
- Neos just got a new approval but slumped 5% possibly on cash crunch worries.
Avisol Capital Partners, managed by Drs Udaya Maiya and Ashok Dutta, is writing a daily scoop of all sorts of news, catalysts, ratings, and other actionable details for its watch list stocks (and the rest of the healthcare universe). The watch list is available to Total Pharma Tracker subscribers. Some sections, like the catalyst data, abstract selections, AdComm coverages, Buy/Sell summaries etc are also available to subscribers only. This is an abridged version; for the entire Pharma Scoop, please subscribe to our Marketplace service.
Our daily analysis of a stock with a major event/upside: ACADIA’s Growth Potential With Nuplazid
The full unabridged post was first published, and can be accessed, on SeekingAlpha Marketplace.